Marksans Pharma Limited has informed the Exchange regarding a press release dated November 19, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC)".

Regulatory product approvalBusiness Updates View source PDF Explain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹192.08

prior close

₹190.90

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.2%-1.6% vs market

Pharmaceuticals peers, median of 156sector-0.5%-1.3% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.6

15m

-0.9

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-0.2-1.6-0.5-1.3

Next day

+0.6-0.5+1.1-0.6+1.2

-0.2-2.0+1.8-1.3+1.1

-2.0-2.6+0.6-2.4+0.4

-1.3-2.5+1.2-2.0+0.7

-0.7-1.2+0.5-1.3+0.6

-2.1-1.7-0.4-1.6-0.6

15d

-1.1-5.6+4.5-3.5+2.4

-4.5-5.0+0.5-4.0-0.5

-9.7-9.0-0.7-6.7-3.0

-7.5-7.7+0.2-9.7+2.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marksans Pharma's wholly owned US subsidiary, Marksans Pharma Inc., has received approval from the USFDA to market Loperamide Hydrochloride Tablets USP, 2 mg as an over-the-counter (OTC) product in the United States. Loperamide is a commonly used anti-diarrheal medication. The approval allows the company to manufacture and sell this generic OTC drug in the US market through its subsidiary. No specific revenue projections or commercial timelines were disclosed in the announcement. This adds to the company's portfolio of US-approved products.

Likely market impact

Positive for shareholders — USFDA approval unlocks access to the large US OTC market for a high-demand generic drug, potentially adding to future US revenue, though the announcement does not specify the financial magnitude.